On June 13, 2022, the US FDA approved the phase I clinical trial of the RJV001 (NCT04821648). A total of 18 patients were enrolled and reached the end of the study, and all three doses were safe and well-tolerated. The ultrasound results showed reduced fat tissue thickness for the exploratory purpose of efficacy. The phase I clinical trial results indicated that RJV001 with mild side effects and early signs of efficacy. The phase II clinical trial protocol is currently in preparation.
